title: Evaluating the Prognostic Value of microRNA-203 in Solid Tumors Based on a Meta-Analysis and the Cancer Genome Atlas (TCGA) Datasets.
abstract: BACKGROUND
  It has been reported that miR-203 expression was aberrant in various types of cancers, and it could be used as a prognostic biomarker. Therefore, in this study, we aimed to evaluate the prognostic value of miR-203 expression in solid tumors by using meta-analysis and The Cancer Genome Atlas (TCGA) datasets.
  
  
  METHODS
  By doing a literature research in PubMed, Embase and the Cochrane Library (last update by December 2016), we were able to identify the studies assessing the prognostic role of miR-203 in various tumors. We then used TCGA datasets to validate the results of meta-analysis.
  
  
  RESULTS
  33 studies from 26 articles were qualified and enrolled in this meta-analysis. Pooled analyses showed that higher expression of miR-203 in tissues couldn't predict poor overall survival (OS) and progression-free survival (PFS) in solid tumors. However, the results of subgroup analyses revealed that the upregulation of tissue miR-203 expression was associated with poor OS in colorectal cancer (hazard ratio (HR)=1.81, 95% confidence intervals (CI) 1.31-2.49; P<0.001), pancreatic cancer (HR=1.19, 95% CI 1.09-1.31; P<0.001) and ovarian cancer (HR=1.85, 95% CI 1.45-2.37; P<0.001); but it had opposite association in liver cancer (HR=0.52, 95% CI 0.28-0.97; P=0.040) and esophageal cancer (HR=0.41, 95% CI 0.25-0.66; P<0.001). Based on TCGA datasets, we found the same results for pancreatic cancer and esophageal cancer, but not for colorectal cancer and liver cancer. Moreover, patients with high circulating miR-203 in blood had significantly poor OS and PFS in colorectal cancer and breast cancer.
  
  
  CONCLUSIONS
  Our study showed that the prognostic values of tissue miR-203 varied in different tumor types. In addition, the upregulation of circulating miR-203 in blood was associated with poor prognosis in colorectal cancer and breast cancer.
authors.affiliation: Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Shao
authors.affiliation: Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
authors.forename: Wendong
authors.initials: W
authors.lastname: Gu
authors.affiliation: Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
authors.forename: Zhonghua
authors.initials: Z
authors.lastname: Ning
authors.affiliation: Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Song
authors.affiliation: Department of Radiation Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
authors.forename: Honglei
authors.initials: H
authors.lastname: Pei
authors.affiliation: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
authors.forename: Jingting
authors.initials: J
authors.lastname: Jiang
mesh_terms: D066264:Datasets as Topic; D018572:Disease-Free Survival; D015894:Genome, Human; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis*; D009369:Neoplasms / Q000378:metabolism* / Q000401:mortality*; D012334:RNA, Neoplasm / Q000096:biosynthesis*; D015996:Survival Rate
chemical_list: C546703:MIRN203 microRNA, human; D035683:MicroRNAs; D012334:RNA, Neoplasm
keywords: Meta-analysis; MicroRNA-203; Prognosis; TCGA; Tumor